van Oterendorp, Christian

[["dc.bibliographiccitation.firstpage","168"],["dc.bibliographiccitation.journal","Experimental Eye Research"],["dc.bibliographiccitation.lastpage","173"],["dc.bibliographiccitation.volume","166"],["dc.contributor.author","Wecker, Thomas"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.author","Reichardt, Wilfried"],["dc.date.accessioned","2020-12-10T14:24:00Z"],["dc.date.available","2020-12-10T14:24:00Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1016/j.exer.2017.10.017"],["dc.identifier.issn","0014-4835"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72100"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Functional assessment of the aqueous humour distal outflow pathways in bovine eyes using time-of-flight magnetic resonance tomography"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Investigative Ophthalmology & Visual Science"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.author","Mans, Viktoria"],["dc.contributor.author","Fischer, Charlotte"],["dc.contributor.author","Khattab, Mohammed"],["dc.contributor.author","Wecker, Thomas"],["dc.date.accessioned","2018-11-07T10:08:43Z"],["dc.date.available","2018-11-07T10:08:43Z"],["dc.date.issued","2016"],["dc.identifier.isi","000394174001307"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39521"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Assoc Research Vision Ophthalmology Inc"],["dc.publisher.place","Rockville"],["dc.relation.conference","Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO)"],["dc.relation.eventlocation","Seattle, WA"],["dc.relation.issn","1552-5783"],["dc.relation.issn","0146-0404"],["dc.title","12% fat milk as OCT contrast agent for ex vivo imaging."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","585"],["dc.bibliographiccitation.journal","Data in Brief"],["dc.bibliographiccitation.lastpage","589"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Wecker, Thomas"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.author","Reichardt, Wilfried"],["dc.date.accessioned","2020-12-10T14:23:28Z"],["dc.date.available","2020-12-10T14:23:28Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1016/j.dib.2018.03.018"],["dc.identifier.issn","2352-3409"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/71932"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Quantitative evaluation of an optimized Time of Flight Magnetic Resonance Imaging procedure using a phantom setup to simulate aqueous humor flow"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Investigative Ophthalmology & Visual Science"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Striebe, Nina-Antonia"],["dc.contributor.author","Khattab, Mohammed"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.date.accessioned","2018-11-07T10:08:44Z"],["dc.date.available","2018-11-07T10:08:44Z"],["dc.date.issued","2016"],["dc.identifier.isi","000394210601025"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39524"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Assoc Research Vision Ophthalmology Inc"],["dc.publisher.place","Rockville"],["dc.relation.conference","Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO)"],["dc.relation.eventlocation","Seattle, WA"],["dc.relation.issn","1552-5783"],["dc.relation.issn","0146-0404"],["dc.title","Is micropulse diode laser photocoagulation effective in treating recalcitrant chronic central serous chorioretinopathy?"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Ophthalmology Retina"],["dc.contributor.author","Lauermann, Peer"],["dc.contributor.author","Klingelhöfer, Anthea"],["dc.contributor.author","Mielke, Dorothee"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Striebe, Nina-Antonia"],["dc.contributor.author","Storch, Marcus Werner"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Koscielny, Juergen"],["dc.contributor.author","Feltgen, Nicolas"],["dc.date.accessioned","2021-06-01T10:49:52Z"],["dc.date.available","2021-06-01T10:49:52Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1016/j.oret.2021.04.013"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86440"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.issn","2468-6530"],["dc.title","Risk factors for Severe Bleeding Complications in Vitreoretinal Surgery and the Role of Antiplatelet or Anticoagulant Agents"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","397"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Investigative Ophthalmology & Visual Science"],["dc.bibliographiccitation.lastpage","406"],["dc.bibliographiccitation.volume","60"],["dc.contributor.author","Gottschalk, Hanna M."],["dc.contributor.author","Wecker, Thomas"],["dc.contributor.author","Khattab, Mohammed H."],["dc.contributor.author","Fischer, Charlotte V."],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Rehfeldt, Florian"],["dc.contributor.author","Lubjuhn, Roswitha"],["dc.contributor.author","Russmann, Christoph"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","van Oterendorp, Christian"],["dc.date.accessioned","2019-07-09T11:50:10Z"],["dc.date.available","2019-07-09T11:50:10Z"],["dc.date.issued","2019"],["dc.description.abstract","Purpose: Contrast agents applicable for optical coherence tomography (OCT) imaging are rare. The intrascleral aqueous drainage system would be a potential application for a contrast agent, because the aqueous veins are of small diameter and located deep inside the highly scattering sclera. We tested lipid emulsions (LEs) as candidate OCT contrast agents in vitro and ex vivo, including milk and the anesthetic substance Propofol. Methods: Commercial OCT and OCT angiography (OCTA) devices were used. Maximum reflectivity and signal transmission of LE were determined in tube phantoms. Absorption spectra and light scattering was analyzed. The anterior chamber of enucleated porcine eyes was perfused with LEs, and OCTA imaging of the LEs drained via the aqueous outflow tract was performed. Results: All LEs showed a significantly higher reflectivity than water (P < 0.001). Higher milk lipid content was positively correlated with maximum reflectivity and negatively with signal transmission. Propofol exhibited the best overall performance. Due to a high degree of signal fluctuation, OCTA could be applied for detection of LE. Compared with blood, the OCTA signal of Propofol was significantly stronger (P = 0.001). As a proof of concept, time-resolved aqueous angiography of porcine eyes was performed. The three-dimensional (3D) structure and dynamics of the aqueous outflow were significantly different from humans. Conclusions: LEs induced a strong signal in OCT and OCTA. LE-based OCTA allowed the ability to obtain time-resolved 3D datasets of aqueous outflow. Possible interactions of LE with inner eye's structures need to be further investigated before in vivo application."],["dc.identifier.doi","10.1167/iovs.18-25223"],["dc.identifier.pmid","30682210"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15874"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59715"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1552-5783"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Lipid Emulsion-Based OCT Angiography for Ex Vivo Imaging of the Aqueous Outflow Tract."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","100031"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Ophthalmology Science"],["dc.bibliographiccitation.volume","1"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Heins, Amelie"],["dc.contributor.author","Lauermann, Peer"],["dc.contributor.author","Storch, Marcus Werner"],["dc.contributor.author","Khattab, Mohammed Haitham"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","van Oterendorp, Christian"],["dc.date.accessioned","2022-05-13T06:27:45Z"],["dc.date.available","2022-05-13T06:27:45Z"],["dc.date.issued","2021"],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.1016/j.xops.2021.100031"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/107850"],["dc.language.iso","en"],["dc.relation.issn","2666-9145"],["dc.rights","CC BY-NC-ND 4.0"],["dc.title","Reliability of Subjective Assessment of Spectral-Domain OCT Pathologic Features by Multiple Raters in Retinal Vein Occlusion"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2753"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Graefe s Archive for Clinical and Experimental Ophthalmology"],["dc.bibliographiccitation.lastpage","2760"],["dc.bibliographiccitation.volume","251"],["dc.contributor.author","Jordan, Jens F."],["dc.contributor.author","Wecker, Thomas"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.author","Anton, Alexandra"],["dc.contributor.author","Reinhard, Thomas"],["dc.contributor.author","Boehringer, Daniel"],["dc.contributor.author","Neuburger, Matthias"],["dc.date.accessioned","2018-11-07T09:17:02Z"],["dc.date.available","2018-11-07T09:17:02Z"],["dc.date.issued","2013"],["dc.description.abstract","In most forms of open angle glaucoma, the trabecular meshwork is the main barrier for aqueous humor outflow, causing elevated intraocular pressure (IOP). The Trabectome is a minimal invasive device for the surgical treatment of open angle glaucoma, particularly eliminating the juxtacanalicular meshwork. This study was conducted to compare the effectiveness and complication profile among different glaucoma subgroups. Single center prospective observational study. There were 557 consecutive eyes of 487 patients included in this study. Trabectome surgery was performed either alone or in combination with cataract surgery. Intraoperative and postoperative complications were documented systematically. Main outcome measures were IOP reduction over time and the preoperative and postoperative number of IOP-lowering medications. Due to subgroup sizes, only data from eyes with primary open angle glaucoma and pseudoexfoliation glaucoma were processed for statistical analysis. For the 261 eyes classified as primary open angle glaucoma, preoperative IOP was 24 +/- 5.5 mmHg (mean +/- SD) under 2.1 +/- 1.3 IOP-lowering medications. After a mean follow-up of 204 +/- 238 days, IOP was reduced to 18 +/- 6.1 mmHg, and medication was reduced to 1.2 +/- 1.1. For the 173 eyes classified as pseudoexfoliation glaucoma, after a mean follow-up of 200 +/- 278 days, IOP was reduced from 25 +/- 5.9 mmHg to 18 +/- 8.2 mmHg, and medication was reduced from 2.0 +/- 1.2 to 1.1 +/- 1.1. A Cox proportional hazards model hinted forward superiority of the combined surgery cases (Trabectome + Phaco + intraocular lens) in comparison to Trabectome surgery only in phakic or pseudophakic eyes. No serious complications were observed. Minimal invasive glaucoma surgery with the Trabectome seems to be safe and effective. The subgroup analysis of different kinds of open angle glaucomas presented in this study may help in first-line patient selection. The lack of ocular surface alterations makes it a valuable addition to glaucoma surgery."],["dc.identifier.doi","10.1007/s00417-013-2500-7"],["dc.identifier.isi","000328345000012"],["dc.identifier.pmid","24158374"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10945"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28070"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1435-702X"],["dc.relation.issn","0721-832X"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Trabectome surgery for primary and secondary open angle glaucomas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","658"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Investigative Ophthalmology & Visual Science"],["dc.bibliographiccitation.lastpage","665"],["dc.bibliographiccitation.volume","55"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.author","Sgouris, Stavros"],["dc.contributor.author","Schallner, Nils"],["dc.contributor.author","Biermann, Julia"],["dc.contributor.author","Lagreze, Wolf A."],["dc.date.accessioned","2018-11-07T09:44:18Z"],["dc.date.available","2018-11-07T09:44:18Z"],["dc.date.issued","2014"],["dc.description.abstract","PURPOSE. Neurotrophic deprivation is considered an important event in glaucomatous retinal ganglion cell (RGC) death. However, the mitogen-activated protein kinase (MAPK) pathway transmitting axonal neurotrophic signals in RGC has not been identified. We investigated the involvement of ERK5 and ERK1/2 in retrograde axonal neurotrophic signaling in rats. METHODS. Adult Sprague-Dawley rats were used. Retinal immunostaining for ERK5 and MEK5 was performed. Levels of total and phosphorylated ERK5 and ERK1/2 were analyzed in retinal lysate by quantitative Western blotting. The effects of age, brain-derived neurotrophic factor (BDNF) stimulation at RGC soma (intravitreal injection) or axon ending (superior colliculus [SC] injection), axonal tyrosine kinase receptor (Trk) receptor inhibition with genistein, and acute axonal damage by optic nerve transection (ONT) were investigated at time points from 24 hours to 5 days. RESULTS. ERK5 and MEK5 were present in RGCs and glial cells. Phospho-ERK5 levels increased in retina and decreased in brain with age (n = 4; P = 0.039). Phosphorylation of ERK5 but not ERK1/2 was increased or decreased by SC injection of BDNF or genistein, respectively (BDNF at 48 hours [p-ERK5: P = 0.01; p-ERK1/2: P = 0.55, n = 8]; genistein at 48 hours [p-ERK5: P = 0.01; p-ERK1/2: P = 0.5, n = 5]). ONT showed a similar trend. BDNF stimulation at the RGC soma increased both p-ERK5 and p-ERK1/2 (P = 0.035 and P = 0.032, respectively; n = 6; at 48 hours). CONCLUSIONS. ERK5 is present in RGCs. Retina and brain p-ERK5 levels develop differently with age. The response of ERK5 but not ERK1/2 to BDNF stimulation or inhibition at the RGC axon ending indicates that retrograde neurotrophic signals in the rat optic nerve may be mediated by the ERK5 pathway."],["dc.identifier.doi","10.1167/iovs.13-12985"],["dc.identifier.isi","000331891700004"],["dc.identifier.pmid","24398098"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34363"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Assoc Research Vision Ophthalmology Inc"],["dc.relation.issn","1552-5783"],["dc.relation.issn","0146-0404"],["dc.title","Retrograde Neurotrophic Signaling in Rat Retinal Ganglion Cells Is Transmitted via the ERK5 but Not the ERK1/2 Pathway"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e010956"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","BMJ Open"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Diem, Ricarda"],["dc.contributor.author","Molnar, Fanni"],["dc.contributor.author","Beisse, Flemming"],["dc.contributor.author","Gross, Nikolai"],["dc.contributor.author","Drueschler, Katharina"],["dc.contributor.author","Heinrich, Sven P."],["dc.contributor.author","Joachimsen, Lutz"],["dc.contributor.author","Rauer, Sebastian"],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Suehs, Kurt-Wolfram"],["dc.contributor.author","Linker, Ralf Andreas"],["dc.contributor.author","Huchzermeyer, Cord"],["dc.contributor.author","Albrecht, Philipp"],["dc.contributor.author","Hassenstein, Andrea"],["dc.contributor.author","Aktas, Orhan"],["dc.contributor.author","Guthoff, Tanja"],["dc.contributor.author","Tonagel, Felix"],["dc.contributor.author","Kernstock, Christoph"],["dc.contributor.author","Hartmann, Kathrin"],["dc.contributor.author","Kuempfel, Tania"],["dc.contributor.author","Hein, Katharina"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.author","Grotejohann, Birgit"],["dc.contributor.author","Ihorst, Gabriele"],["dc.contributor.author","Maurer, Julia"],["dc.contributor.author","Mueller, Matthias"],["dc.contributor.author","Volkmann, Martin"],["dc.contributor.author","Wildemann, Brigitte"],["dc.contributor.author","Platten, Michael"],["dc.contributor.author","Wick, Wolfgang"],["dc.contributor.author","Heesen, Christoph"],["dc.contributor.author","Schiefer, Ulrich"],["dc.contributor.author","Wolf, Sebastian"],["dc.contributor.author","Lagreze, Wolf A."],["dc.date.accessioned","2018-11-07T10:20:35Z"],["dc.date.available","2018-11-07T10:20:35Z"],["dc.date.issued","2016"],["dc.description.abstract","Introduction Optic neuritis leads to degeneration of retinal ganglion cells whose axons form the optic nerve. The standard treatment is a methylprednisolone pulse therapy. This treatment slightly shortens the time of recovery but does not prevent neurodegeneration and persistent visual impairment. In a phase II trial performed in preparation of this study, we have shown that erythropoietin protects global retinal nerve fibre layer thickness (RNFLT-G) in acute optic neuritis; however, the preparatory trial was not powered to show effects on visual function. Methods and analysis Treatment of Optic Neuritis with Erythropoietin (TONE) is a national, randomised, double-blind, placebo-controlled, multicentre trial with two parallel arms. The primary objective is to determine the efficacy of erythropoietin compared to placebo given add-on to methylprednisolone as assessed by measurements of RNFLT-G and low-contrast visual acuity in the affected eye 6months after randomisation. Inclusion criteria are a first episode of optic neuritis with decreased visual acuity to 0.5 (decimal system) and an onset of symptoms within 10days prior to inclusion. The most important exclusion criteria are history of optic neuritis or multiple sclerosis or any ocular disease (affected or non-affected eye), significant hyperopia, myopia or astigmatism, elevated blood pressure, thrombotic events or malignancy. After randomisation, patients either receive 33000 international units human recombinant erythropoietin intravenously for 3 consecutive days or placebo (0.9% saline) administered intravenously. With an estimated power of 80%, the calculated sample size is 100 patients. The trial started in September 2014 with a planned recruitment period of 30months. Ethics and dissemination TONE has been approved by the Central Ethics Commission in Freiburg (194/14) and the German Federal Institute for Drugs and Medical Devices (61-3910-4039831). It complies with the Declaration of Helsinki, local laws and ICH-GCP. Trial registration number NCT01962571."],["dc.identifier.doi","10.1136/bmjopen-2015-010956"],["dc.identifier.isi","000374052300146"],["dc.identifier.pmid","26932144"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13259"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41917"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bmj Publishing Group"],["dc.relation.issn","2044-6055"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trialstudy protocol"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]